Differences in pharmacological pathways among Qingkailing effective component / 中国药理学通报

ABSTRACT

AimPurpose-The aim of this study is utilizing the highthrough genechip data to Compare the difference of the pharmacological pathways among the Qingkailing effective components Baicalin(BA),Jasminoidin(JA),cholic acid(CA) and Concha margaritiferausta(CM)in the treatment process of cerebral ischemia.Methods The focal cerebral ischemia-reperfusion model mice were randomly divided into groups of Baicalin(BA),Jasminoidin(JA),cholic acid(CA),Concha margaritiferausta(CM)and model group(M),15 mice for each group,24 hours later total RNA were abstracted from the hippocampus,we selected 374 gene expression profile related to cerebral ischemia,made cDNA chip marked by Cy3/Cy5,detect the variation of different components,Then apply Arraytrack software to select differentiate expressed genes between BA and M,JA and M,CA and M,CM and M by T-tests,select genes with P<0.05,Fold change>1.5,according GeneGO software to find the top two pathways of each components.Results the number of differentiate expressed genes between BA,JA,CA,CM and M is separately 46,50,54 and 30,according to the top two pathways of GeneGo display JA,CA,CM all participate Apoptosis and survival_TNFR1 signaling pathway,besides BA participate in regulating G-protein signaling and Development_A2A receptor signaling while CA in Neurophysiological process_NMDA-dependent postsynaptic long-term potentiation in CA1 hippocampal.Conclusion Qingkailing effective components take diversity Pharmacological characteristics,BA mainly for anti-apoptosis,JA mainly for inhibit apoptosis and promote ischemic brain protection,etc,CA focused on inhibiting calcium influx,and anti-neuron variability.But CM has no good results on this.